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I.

EXECUTIVE SUMMARY

Proposition 61 seeks to lower the prices the State of California pays for prescription
medications to the same price or less than what is paid by the Department of Veteran Affairs
(VA) for any particular medication. The price paid by the VA is by far the lowest price paid to
drug manufacturers by any government agency. Proposition 61 has the potential to save the state
funds, but it is impossible to predict how prescription medication manufacturers will respond to
this proposition should it be enacted. This measure exempts most of Medi-Cal’s managed care
plans, which provide health insurance coverage to the majority of the state’s low-income
individuals. Additionally, this measure restricts the state when buying prescription medications
directly from pharmaceutical manufacturers or when reimbursing pharmacies for recipients’
medications by setting a maximum price the state can pay. However, it is important to note that
under federal law all Medicaid programs (Medi-Cal in California) are required to cover all
medications that have been approved by the United States Food and Drug Administration (FDA),
and, if manufacturers declined to offer prescription medications at the lowest price paid by the
VA, the state would probably have to offer the medications anyway under federal law.
A YES VOTE means that any state agency would be prohibited from paying more for
prescription medications than is paid by the VA for the same prescription medication. This
measure exempts most Medi-Cal Managed Care Programs from the required spending limits.
A NO VOTE means that when state agencies are negotiating and paying for prescription
medications, no reference to the prices paid by the VA would be required.
II. THE LAW
A. The Path To The Ballot
In the United States, we spend twice as much on healthcare per capita than other
advanced countries, but we are not living any longer than those who are spending less.1 In the
1990s, prescription medications accounted for 7 percent of total healthcare costs, including
physician visits, prescription drugs, hospital care and home nursing care.2 In recent years, the
number has increased to 17 percent, according to the United States Health and Human Services
Department.3 The cost of medications varies between generic and brand name medications.
Brand name medications are protected from competitors due to their patent and are typically
more expensive.4 Generic medications can be purchased for a cheaper rate, however, the price of
generic medication depends on the competition for the medication in the market.5 Once a patent
1

Joint Senate and Assembly Health Committee Informational Hearing on Proposition 61, May 10, 2016. Available
at http://senate.ca.gov/media-archive?title=&startdate%5Bvalue%5D%5Bdate%5D=05-102016&enddate%5Bvalue%5D%5Bdate%5D=05-10-2016# (on file with the California Initiative Review).
2
Melody Peterson, Here’s Why Drug Prices Rise Even When There’s Plenty of Competition, L.A. TIMES (September
5, 2016), http://www.latimes.com/business/la-fi-mylan-price-hikes-20160830-snap-story.html (on file with
the California Initiative Review).
3
Id.
4
Id.
5
Questions and Answers, FDA U.S. FOOD & DRUG ADMINISTRATION (September 5, 2016),
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm100100.htm (on file with
the California Initiative Review).
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has expired, generic drug manufacturers will compete with the original patent holder to make the
medication.6 This competition used to drive down costs for medications, but today medication
prices continue to rise.7
The price of an EpiPen, a device that counteracts life-threatening allergies by injecting
epinephrine directly into someone experiencing an allergic reaction, has increased by 547
percent since 2007.8 The EpiPen has gone from $94 in 2007 to $608 today, far exceeding the
average rate of inflation.9 Similarly, Daraprim, which treats patients with the parasite-borne
disease toxoplasmosis, has increased from $13.50 per pill in 2015, to $750 per pill today.10 The
treatment regimen consists of two pills per day for two weeks, which equates to an increase from
$1,130 to $63,000 for a treatment cycle.11 A Hepatitis C medication, Sovaldi, has doubled in
price since 2011, and another Hepatitis C medication, Harvoni, is even more expensive than
Sovaldi.12
State legislation to bring light to the issue of medication pricing transparency has failed.
Senator Ed Hernandez and Assemblyman David Chiu each introduced bills in the 2015-2016
regular session that would have helped bring prescription drug prices to the public’s attention.13
Assembly Bill 463 (Chiu) would have required manufacturers with medications with a cost of
$10,000 or more annually to file a report.14 Senate Bill 1010 (Hernandez) would have required
health care service plans or health insurers to file cost specific information regarding the cost of
prescription medications.15 But, Sen. Hernandez pulled his bill due to amendments that limited
its efficacy, and Assemblyman Chiu’s bill was held in committee.16
Michael Weinstein, President of AIDS Healthcare Foundation, wanted to bring
Proposition 61 to a vote of the people in the hope that it would lower the prices of prescription
medications paid for by the state.17 Based in Los Angeles, the AIDS Healthcare Foundation is
the largest provider of AIDS/HIV healthcare services in the United States.18 There is a
difference in the financial campaigning power between the support and opposition. As of
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Peterson, supra note 2.
Id.
8
Id.
9
Id; Inflation Data: Average rate is 3.2 percent; Tim Mcmahon, Long Term U.S. Inflation. INFLATIONDATA.COM
(September 10, 2016), http://inflationdata.com/Inflation/Inflation_Rate/Long_Term_Inflation.asp (on file with
the California Initiative Review).
10
Michael Hiltzik, A Huge Spike in the Cost of an Old Drug Reignites the Pharma Pricing Debate, L.A. TIMES
(September 22, 2016), http://www.latimes.com/business/hiltzik/la-fi-mh-a-huge-spike-in-the-cost-of-an-olddrug-20150921-column.html (on file with the California Initiative Review).
11
Id.
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Id.
13
Tracy Seipel, California’s Prop. 61 Seeks to Lower Drug Prices, Increase Transparency, THE MERCURY NEWS
(September 6, 2016), (on file with the California Initiative Review).
14
AB 462, 2016 Leg., 2015–2016 Reg. Sess. (Cal. 2016) (as amended on Jan. 4, 2016, but not enacted).
15
SB 1010, 2016 Leg., 2015–2016 Reg. Sess. (Cal. 2016) (as amended on Aug. 16, 2016, but not enacted).
16
Seipel, supra note 13.
17
Andrew Pollack, California Drug Price Plan is Criticized by Patient Advocates, N.Y. TIMES (August 28, 2016)
http://www.nytimes.com/2016/07/05/business/california-drug-price-plan-is-criticized-by-patientadvocates.html?_r=1 (on file with the California Initiative Review).
18
Id.
7
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October 2, 2016, the opposition has raised $86 million while support for this proposition has
raised $14.5 million.19
Weinstein also initiated a similar initiative in Ohio, titled “Ohio Drug Price Relief Act.”20
The Ohio initiative process differs slightly from California. Ohio is an indirect initiative state,
and Ohio law requires two installments of signatures.21 The first installment requires the
proponents to collect signatures totaling at least 3 percent of the votes in the last gubernatorial
election to get the initiative to the legislature.22 If the legislature does not move on the initiative,
the proponents may collect additional signatures, totaling 3 percent of the vote in the last
gubernatorial election, to be placed on the ballot for the people to vote on.23 At the end of both
installments, the total amount of signatures collected should equal 6 percent of the total votes in
the last gubernatorial election.24
The Ohio Initiative was challenged for lacking sufficient signatures by Pharmaceutical
Research and Manufacturers of America (PhRMA) and the Ohio Chamber of Commerce.25 The
Court initially upheld the challenge, but within another lawsuit regarding the same signatures,
the court decided to count the signatures.26 The Ohio Initiative was then allowed to proceed
collecting more signatures to qualify for the ballot.27 The initiative will be on the November
2017 ballot in Ohio.28
B. Possible Alternative Solutions
During an informational joint committee hearing on Proposition 61 held by the
Legislature on May 10, 2016, Assemblymember David Chiu asked both supporters and
opponents of Proposition 61 if they agreed that something must be done about prescription drug
prices.29 All parties were able to agree on that point.30 However, when Assemblymember Chiu
asked if the opponents had a better solution to propose, they were silent.31 One of the solutions
that Assemblymember Chiu suggested was that most other developed countries, like Canada,
have set ratio limits on the amount of profit manufacturers are allowed to make on prescription
medications.32
19

California Proposition 61, Drug Price Standards (2016), BALLOTPEDIA (August 22, 2016),
https://ballotpedia.org/California_Proposition_61,_Drug_Price_Standards_(2016) (on file with the California
Initiative Review).
20
Id.
21
Ohio Drug Price Standards Initiative (2017), BALLOTPEDIA (August 29, 2016),
https://ballotpedia.org/Ohio_Drug_Price_Standards_Initiative_(2017) (on file with the California Initiative
Review).
22
OHIO CONST. art 2, sec. 1.
23
Id.
24
Id.
25
Ohio Drug Price Standards Initiative (2017), BALLOTPEDIA (August 29, 2016)
https://ballotpedia.org/Ohio_"Drug_Price_Relief_Act"_Initiative_(2017) (on file with the California Initiative
Review).
26
Id.
27
Id.
28
Joint Senate and Assembly Health Committee Informational Hearing on Proposition 61, supra note 1.
29
Id.
30
Id.
31
Id.
32
Id.
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Federal legislation attempting to link Medicaid prescription pricing to the VA in the past
has failed, leaving most states attempting to resolve escalating prescription drug costs on their
own. Vermont passed a law, S.216, requiring drug manufacturers to justify their price increases
for some medications.33 In Texas, House Bill Number 4002, will initiate a joint interim study to
discover the reasons behind prescription drug pricing increases.34 New York is also considering
capping the prices its Medicaid program pays for some prescription medications.35 Virginia,
Oregon, Pennsylvania, North Carolina and Massachusetts had proposals regarding drug pricing
transparency that have not passed.36 For example, in Massachusetts, Senate No. 1048 was
introduced to promote cost transparency.37 Likewise, in Virginia, House Bill 113 would require
drug transparency for medication with a wholesale acquisition of $10,000 or more to report costs
associated with the drug to report to the Commissioner.38
C. EXISTING LAW
1. Overview of State Prescription Medication Spending
California pays for prescription medications for those who are covered by Medi-Cal
County Organized Health Systems, Medi-Cal Fee-For-Service Programs, Medi-Cal for
individuals with moderate to severe mental health disorders, current and retired state employees,
students in the University of California and California State University systems, inmates,
uninsured individuals who are HIV positive, state hospital patients and developmental center
residents.39 The state is the ultimate payer of medications when it either negotiates directly with
manufacturers or reimburses pharmacies for drugs they have dispensed to patients covered under
a state program.40 Annual state drug expenditures totaled $3.8 billion in 2015–16.41 State funds
pay for half of overall state prescription drug spending and the remainder comes from the federal
government and other non-state revenues.42
2. State Negotiation Strategies for Prescription Prices
The State has many strategies it may use when negotiating for discounted prices with
manufacturers and wholesalers. State agencies may decide to negotiate together or
33

S 216, 2016 Leg., 2015–2015 Reg. Sess. (VT. 2016).
HB 4002, 2015 Leg., 2015 Leg. Ses.. (TX. 2015) (as introduced Mar. 13, 2015, but not enacted).
35
Ed Silverman, NY Governor Andrew Cuomo Seeks to Cap Some Drug Prices, STAT (September 2, 2016) available
at https://www.statnews.com/pharmalot/2016/01/22/new-york-andrew-cuomo-drug-prices/ (on file with the
California Initiative Review).
36
Fran Quigley, Disgusted with Sky-High Drug Prices, California Voters Take on Big Pharma, TRUTHOUT (August
28, 2016) available at http://www.truth-out.org/news/item/37260-disgusted-with-sky-high-drug-pricescalifornia-voters-take-on-big-pharma (on file with the California Initiative Review).
37
Complete Text of Bill S.1048, https://malegislature.gov/Bills/189/Senate/S1048 (last visited October 18,
2016)
38
Complete Text of HB 1113, https://lis.virginia.gov/cgi-bin/legp604.exe?161+ful+HB1113 (last visited
October 18, 2016)
39
CAL. SEC’Y OF STATE, OFFICIAL VOTER INFORMATION GUIDE: CALIFORNIA GENERAL ELECTION, TUESDAY
NOVEMBER 8, 2016, available at http://vig.cdn.sos.ca.gov/2016/general/en/pdf/complete-vig.pdf [“NOVEMBER 2016
VOTER GUIDE”].
40
Id.
41
Id.
42
Id.
34
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individually.43 When agencies decide to negotiate together, they are able to get better prices due
to the larger population they serve.44 Additionally, this lessens the administrative costs of
negotiating prices.45
State agencies also negotiate for lower prices by removing administrative procedures that
can create obstacles to prescribing medications, such as prior approval before the medication can
be prescribed.46 By agreeing to remove these administrative procedures, state agencies are also
able to individually negotiate supplemental rebates that result in additional savings for the state
on certain medications.47
3. Federal Prescription Medication Spending
a. Medicaid Price Ceilings
The federal government has placed price caps on the maximum prices that manufacturers
can charge Medicaid programs.48 Because Medi-Cal is the State’s extension of Medicaid, those
price caps on manufacturers apply directly to Medi-Cal.49
b. United States Department of Veteran Affairs Overview
The VA negotiates medication pricing with prescription manufactures based on federal
contract laws and regulations.50 The VA uses different categories of prices, negotiated based on
how prescription manufacturers do business with their commercial customers. Under the
Veterans Health Care Act of 1992, the VA pricing is either negotiated at the vendor’s most
favored commercial customer price or statutorily required pricing calculations.51 There are two
different categories of pricing that vendors can participate in. The first category is only available
to the VA.52 The second category of pricing, referred to by the VA as dual pricing, applies to
other Government agencies.53 The VA also uses a national contract program that allows the VA
to obtain prices that are mostly lower than any other agency.54 When the VA negotiates pricing,
they are bound by confidentiality contracts that may not allow for final prices to be posted,
therefore making it uncertain if the medication are lower than agencies.55

43

Id.
Id.
45
Id.
46
Id.
47
Questions and Answers, CALIFORNIA DEPARTMENT OF HEALTH CARE SERVICES (September 4, 2016), available at
http://www.dhcs.ca.gov/provgovpart/Pages/DrugRebateFAQ.aspx - 1 (on file with the California Initiative
Review).
48
NOVEMBER 2016 VOTER GUIDE.
49
Id.
50
Pharmacy Benefits Management Services, UNITED STATES DEPARTMENT OF VETERAN AFFAIRS (September 12,
2016), available at http://www.pbm.va.gov/PharmaceuticalPrices.asp (on file with the California Initiative Review).
51
Id.
52
Id.
53
Id.
54
Id.
55
Id.
44
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Part of the reason the VA is able to get lower prices on medication is because they only
offer a selective list of medications the providers are permitted to prescribe to VA patients,
which creates an incentive for manufacturers to offer lower prices in order for their medications
to be offered to the VA’s 9 million recipients.56 However, according to studies cited at a joint
committee hearing on this proposition, the VA actually pays more than other agencies for name
brand, but less on generic medications.57
c. Confidentiality Agreements
Some of the VA’s contracts are reviewable in a public database that is searchable,
however, the actual price paid may not be disclosed.58 According to federal regulations59, the
government is to treat all information in an offer as confidential.60 There are many prices that the
VA is able to negotiate that are lower than the searchable prices but they do not disclose due to
confidentiality agreements with the manufacturer.61
D. PROPOSED LAW
Proposition 61 would prohibit state agencies from paying more for prescription
medications from a manufacturer than the lowest price paid by the VA for the same drug, except
as required by federal law.62 Proposition 61 would apply to direct purchases by the state agency
as well as indirect purchases where the agency is the “ultimate payer” of the medications.63
The State is the ultimate payer for prescription medications for those who are covered by
Medi-Cal County Organized Health Systems, Medi-Cal Fee-For-Service Programs, Medi-Cal
treatment for individuals with moderate to severe mental health disorders, current and retired
state employees through CalPERS, Students in the University of California and California State
University Systems, Inmates at State institutions, Uninsured individuals who are HIV positive,
State Hospital patients and Developmental Center residents.64
With one out of three Californians enrolled in Medi-Cal, the different Medi-Cal programs
represent a large percentage of the population that could be effected by Proposition 61.65 MediCal has two different types of programs, Fee-For-Service and Managed Care.66 With Fee-ForService coverage, providers and pharmacies are directly reimbursed for the services and
medications they provide.67 The Fee-For-Service Program covers roughly 12 percent of

56

Id.
Joint Senate and Assembly Health Committee Informational Hearing on Proposition 61, supra note 1.
58
Id.
59
48 C.F.R. § 3.104-3 (2012).
60
Joint Senate and Assembly Health Committee Informational Hearing on Proposition 61, supra note 1.
61
Id.
62
NOVEMBER 2016 VOTER GUIDE.
63
Id.
64
Id.
65
Id.
66
Id.
67
Debating the New Ballot Measure to Control Prescription Drug prices, CALIFORNIA HEALTHLINE,
http://californiahealthline.org/news/debating-the-new-ballot-measure-to-control-prescription-drug-prices/
(on file with the California Initiative Review).
57
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Californians enrolled in Medi-Cal.68 The majority of Californians enrolled in Medi-Cal or 88
percent of Medi-Cal enrollees are covered by managed care programs.69 Medi-Cal Managed
Care differs from fee-for-service because the state pays a monthly fee to the health plans for per
capita enrollment irrespective of use of health care services and the plans pay the cost of
prescription medications.70 Proposition 61 exempts most managed care plans but does apply to
those covered under fee-for-service.
Additionally, Proposition 61 would apply to all other programs besides Medi-Cal where
the state is the ultimate payer for medications.71 The proponents claim this includes the 3 million
Medi-Cal patients in the fee-for-service program, the 838,000 state current and retired
employees, 294,000 teachers, and employees of the California State University and University of
California systems.72 The opponents suggest those impacted by this proposition will be only 4.4
million people.73 On the other hand, proponents estimate the number of those affected will be
closer to 5 to 7 million.74
For the populations that will be impacted by Proposition 61, only prescription drugs on
the VA prescription list will have the fixed prices required by the measure.75 The state may
continue to contract as it has been for the prescription medications not on the VA prescription
list.76 This measure would go into effect the day after the measure passes; however, agencies will
be required to comply by July 2017.77
III. DRAFTING ISSUES
A. Binds the State Without Binding Manufacturers to Comply
Proposition 61 only places a requirement on the state to buy a prescription drug at the
lowest price offered paid by the VA; however, the measure does not require that the prescription
drug manufacturers sell their products for VA list prices.78 In this way, the measure ties the
hands of the state without placing any obligations or penalties on drug manufacturers.79 The
proponents argue that this was deliberate in their drafting because only the federal government
has the ability to bind manufacturers as the federal government currently requires certain levels

68

NOVEMBER 2016 VOTER GUIDE.
Id.
70
Joint Senate and Assembly Health Committee Informational Hearing on Proposition 61, supra note 1.
71
NOVEMBER 2016 VOTER GUIDE.
72
Seipel, supra note 13.
73
Id.
74
Id.
75
Debating the New Ballot Measure to Control Prescription Drug prices, CALIFORNIA HEALTHLINE,
http://californiahealthline.org/news/debating-the-new-ballot-measure-to-control-prescription-drug-prices/ (on file
with the California Initiative Review); The VA prices can be viewed here: Pharmacy Benefits Management Services,
UNITED STATES DEPARTMENT. OF VETERAN AFFAIRS (August 29, 2016),
http://www.pbm.va.gov/PharmaceuticalPrices.asp (on file with the California Initiative Review).
76
Id.
77
NOVEMBER 2016 VOTER GUIDE.
78
Joint Senate and Assembly Health Committee Informational Hearing on Proposition 61, supra note 1.
79
Id.
69

8

of prices for Medicaid and the VA.80 Because the federal government regulates prices that can be
charged to Medicaid programs by manufacturers, the federal law would control instead of any
attempt at the state level to restrict prices that manufacturers can charge.81
B. VA Confidentiality Creates Challenges for Enforcement
Prescription drug manufacturers have confidentiality agreements in their contracts with
payers of prescription drugs, including the VA. Proposition 61 may be interpreted in one of two
ways: 1) to require the confidential lower price the VA pays to be publicly disclosed in order for
the state to purchase at those prices or 2) to require that the prices are publicly listed on the VA’s
searchable database. Although it is unknown if the database by the VA displays the most up-todate lowest price paid for by the department, proponents claim that they are satisfied with “most”
of the medications that are publicly displayed.82
The proponents have said that this measure is not about getting the VA to disclose their
prices, but it is about ensuring California’s prices are as low as possible when purchasing
prescription medications from manufacturers.83 At a public informational forum, presented by
Capitol Weekly and Capital Weekly Radio, the proponents claimed that they are not concerned
with the prices being disclosed to the public despite those confidentiality agreements.84
Authors of the proposition tried to file a Freedom of Information Act (“FOIA”) request to
the VA and were denied.85 Additionally, the California Legislative Analyst Office (LAO) and
other state agencies have contacted the VA several times and their requests for disclosure of the
confidential prices have been denied.86 During a joint committee informational hearing, LAO
stated that the only agencies that have access to the private prescription drug costs have federal
audit powers and that was the reason they were able to obtain the information.87 The U.S.
Government Accountability Office has published a report on VA spending, but the numbers they
released on VA medications were normalized to reflect publicly known prices.88
The state agencies affected by Proposition 61 could interpret the proposition to mean that
the price paid by the VA is the public price, rather than the confidential price.89 This is mostly
likely going to be the interpretation most agencies will employ because the VA maintains a
public searchable database offering agencies’ best opportunity to comply with the requirements
of the measure. Additionally, the language of the proposition requires that the state pay the VA
price or lower. If agencies interpret the proposition to mean they negotiate for the lowest public
80

Interview with Arif Aziz, Northern California Coordinator for Yes on Prop 61, September 16, 2016 (on file with
the California Initiative Review).
81
Erwin Chemerinsky, CONSTITUTIONAL LAW, PRINCIPLES AND POLICIES 410 (Wolters Kluwer, 5th ed. 2015).
82
Id.
83
California Votes: 2016 Ballot Measure Forum, THE CALIFORNIA CHANNEL (September 8, 2016) available at (on
file with the California Initiative Review).
84
Id.
85
Id.
86
Joint Senate and Assembly Health Committee Informational Hearing on Proposition 61, supra note 1.
86
Id.
87
Id.
88
Id.
89
Id.
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price on medications, that would be higher than the price the VA actually pays and, thus, gives
agencies more ability to negotiate.
Courts would likely uphold this interpretation because, “an administrative agency
charged with its enforcement and interpretation is entitled to great weight unless it is either
‘arbitrary, capricious or without rational basis' or is ‘clearly erroneous or unauthorized.”90 This
proposition is silent on whether the VA price should be defined as the private or public prices;
therefore, it is highly unlikely a court would say either interpretation of which price level should
apply would be “unreasonable or clearly erroneous.”
IV. CONSTITUTIONAL ANALYSIS
When the federal government has chosen to pass laws or regulate a particular area of law,
because of the supremacy clause in the constitution, the federal law is controlling.91 This practice
is referred to as preemption by the federal government. Under federal law, all state Medicaid
programs are required to offer all prescription medications that are approved by the FDA to
beneficiaries.92 Medi-Cal, as the state’s Medicaid program, will have to disregard the
requirements of this proposition if manufacturers decline to agree to the VA’s price on
prescription medications.93 The state, instead, will have to purchase medications at the best
possible price they are able to negotiate for, regardless of whether the price they pay is less than
the price paid by the VA.
V. PUBLIC POLICY CONSIDERATIONS
A. Programs That Will Be Impacted by This Proposition
Proposition 61 will have an impact on other health coverage programs because the
restrictions on state spending apply whenever the state is the ultimate payer for prescription
medications and not program categories as a whole. The proponents of the proposition claim that
the measure will affect anyone who receives care through Medi-Cal fee-for-service programs, all
current and retired state employees who are overseen by CalPERS, all inmates in corrections
facilities, students that are covered through insurance options provided by the UC and CSU
system, State Hospital patients, uninsured that are HIV positive, and developmental center
residents.94 However, they estimate that only 4.4 million people will be affected by this
proposition.95
1. Managed Care Plans
The exemption of programs like Medi-Cal Managed Care is a direct result of the
language in the proposition that it applies, “to all programs where the State of California or any
state administrative agency or other state entity is the ultimate payer for the drug, even if it did
90

Yamaha Corp. of Am. v. State Bd. of Equalization, 19 Cal. 4th 1, 6-7 (1998).
Erwin Chemerinsky, CONSTITUTIONAL LAW, PRINCIPLES AND POLICIES 410 (Wolters Kluwer, 5th ed. 2015).
92
Id.
93
Id.
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NOVEMBER 2016 VOTER GUIDE.
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Id.
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not purchase the drug directly.”96 However, by reading this language for its plain meaning the
proposition has a different impact than the proponents claim. The State is the “ultimate payer”
for medications when they either purchase medications directly from manufacturers or reimburse
pharmacies.97
Medi-Cal has six different types of managed care models.98 In 5 out of the 6 models of
care delivery, the state essentially pays the plan premiums or a monthly fee cost of enrollment to
the plans for Medi-Cal beneficiaries.99 When the state pays the plans for a beneficiary’s
enrollment, the managed care plans pay for those beneficiaries’ medications and, thus, negotiate
directly with pharmaceutical manufacturers for the best price they will offer Medi-Cal
recipients.100 Under the managed care plan systems, the plans are the ultimate payer of
medications, as opposed to the state.101
However, in the remaining type of managed care plan, called County Organized Health
Systems (COHS), that cover recipients in 22 of California’s 58 counties, the plans are created
and overseen by that county’s Board of Supervisors and all the Medi-Cal beneficiaries in that
particular county are covered by the same county-run managed care plan.102 In the 22 counties
that use County Organized Health Systems, the state reimburses the county for all services and
medications, making the state the ultimate payer for medications.103 Because the state is the
ultimate payer, the 1.9 million beneficiaries in COHS could be affected by the state’s attempts to
comply with this proposition.
The state is also the ultimate payer for medications in the Medi-Cal fee-for-service model
because the state directly pays for the services and medications that are provided to
beneficiaries.104 An additional 4.2 million Medi-Cal beneficiaries in the fee-for-service program
would be affected by the proposition because the State is the ultimate payer of medications and
would have to comply with this proposition.105
2. Impact on Mental Health
Additionally, any Medi-Cal beneficiary who has a moderate to severe mental health
disorder could also be affected by this proposition. Under Medi-Cal, plans cover most of a
beneficiary’s care, but those with moderate to severe mental health disorders receive treatment
directly from the county where they reside.106 The state then pays the cost of care for those with
96

Id.
Id.
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Medi-Cal Managed Care Program Fact Sheet, DHCS, September 28, 2016. available at
http://www.dhcs.ca.gov/provgovpart/Documents/MMCDModelFactSheet.pdf (on file with the California Initiative
Review).
99
Id.
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Id.
101
Id.
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Id.
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San Diego County Adult Medi-Cal Mental Health Severity Analysis. October, 3, 2016. (on File with California
Initiative Review).
97

11

a mental illness directly to the counties.107 The disorders that qualify as moderate to severe
include schizophrenia, major mood disorders such as bipolar disorder, and major anxiety
disorders.108
Any restrictions to medications or failure to prescribe certain medications as a result of
this proposition passing would have a substantial effect on those who suffer from mental health
issues.109 A large percentage of those with mental illness depend on state funding for
medication.110 Of the 13 million Medi-Cal beneficiaries, 65 percent were on antidepressants for
12 weeks and 52 percent were on antidepressants for at least 6 months in 2015.111 There is a very
delicate balance of medications for those with mental health issues and any interruption in
medications could have devastating effects.112 According to the California Psychiatric
Association, an interruption in medications is guaranteed to result in increased hospitalizations
from self-harm and suicide attempts directly related to the symptoms of disorders.113
When someone with a mental illness experiences a gap in medications for just 1 to 10
days their risk of hospitalization doubles.114 When the interruption in medications lasts 10 to 30
days the hospitalization risk triples.115 When the interruption lasts longer than 30 days the
hospitalization risk quadruples.116 These hospitalizations are predictable results and are directly
tied to the symptoms of the disorders people suffer from.117 Getting hospitalized for a mental
health issue is a high threshold for an adult. Someone must be evaluated and determined to be an
immediate danger to themselves or others.118 For adults this often takes an actual suicide attempt
or self-harm.
Additionally, when there are gaps in medication for those with mental health disorders
there is a lag of time between starting the medications again and the medications becoming fully
effective.119 Once someone is placed back on their medications it takes 4 to 6 weeks for most
medications to become fully effective and to stabilize the symptoms of their condition.120 Any
gaps in medication as a result of Proposition 61 would have dangerous effects for those with
mental health issues.121
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B. Proponents Main Arguments
1. Prescription Prices for Medications are Overwhelming
It is no secret that the continuous increase in prices for medications is causing financial
strain for the American people. The increases in prices are especially difficult to bear for those
on fixed or low incomes such as retired individuals.122 Studies have shown that the cost for
specialty medications is higher than the average household income.123 Additionally, a study by
Professor Jeffrey S. Hoch of the Center for Healthcare Policy and Research at U.C. Davis found
that the price of a cancer treatment was six times more than what oncologists thought was
reasonable.124 The proponents and opponents of this proposition both agree that prescription
medication prices are a problem, they just disagree on how to solve this issue.125
2. Requires State to Get Lowest Price on Prescription Medications
Proponents hope that Proposition 61 will require the state to get the best price on
medications to lower the state’s overall drug expenditures. The VA generally pays an average of
20-24 percent less than other agencies and up to 40 percent lower than Medicare part D (MediCal).126 By requiring the state to pay either the same or lower prices as the VA pays for
prescription medications, proponents anticipate that the cost savings will be passed on to
taxpayers.127 The savings could be beneficial to the state because this proposition would apply
whenever the state pays for medications.128 However, the VA does not always get the lowest
price on all medications, as proponents claim. According to studies, the VA actually pays 136
percent more on name brand medications than the Department of Defense (“DOD”).129 However,
those studies also found the DOD pays 60 percent more on generic medications than the VA.130
There is the risk with this proposition that the manufacturers of medications will not
agree to sell their medications at the rate or lower than the rate paid by the VA. The proponents
of this measure do not believe that this will be an issue. They argue that the manufacturers of
medications will take a profit, even if it is less than they would like.131
C. Opponents Main Arguments
1. Hurt Veterans by Increasing Prescription Drug Prices
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Opponents fear that the prices manufacturers charge the VA will increase if this measure
is passed.132 While federal law protects VA pricing, by requiring that the VA gets an automatic
24 percent discount on generic medications, there is still some cause for concern.133 The VA
frequently negotiates with prescription manufacturers to get an additional percentage of up to 40
percent.134 Veterans fear that they will lose this additional bargaining power.135
The fear that VA prices will increase if the state is obligated to get the same price has
proven to be true in the past. In 1990, Congress linked Medicaid prices for medications to the
prices paid by the VA and the prices manufacturers charged VA increased so drastically that a
year later, Congress repealed the connection.136
2. Reduce Patient Access to Medicines
The California Medical Association and CalPERS claim that this measure could interfere
with access to the medications that patients are prescribed.137 The state has negotiated contracts
with pharmaceutical companies for discounted drug pricing, which may become invalid if this
measure passes.138 When manufacturers agree to lower prices for state agencies, the state agrees
to remove administrative procedures that would normally be required to prescribe medications
by placing the medication on a preferred list of prescriptions.139
If the contracts are voided and medications are removed from the preferred prescription
list, then patients and doctors will have to go through a longer process before getting the
prescription medications they need.140 Before being prescribed medications that are not on the
preferred prescription list, patients would have to try other medications until the doctor has
decided that those medications are not treating the patient’s problem or additional administrative

132

Why Veterans Strongly Oppose Prop. 61, NO PROP 61, available at http://www.noprop61.com/facts/impacton-veterans (on file with the California Initiative Review).
133
California Votes: 2016 Ballot Measure Forum, THE CALIFORNIA CHANNEL (September 8, 2016), available at
http://www.calchannel.com/california-votes-2016-ballot-measure-forum/ (on file with the California Initiative
Review).
134
Id.
135
Id.
136
Why Veterans Strongly Oppose Prop. 61, NO PROP 61 (August 22, 2016), available at
http://www.noprop61.com/facts/impact-on-veterans (on file with the California Initiative Review).
137
CMA Calls for Greater Transparency in Prescription Drug Costs, CALIFORNIA MEDICAL ASSOCIATION
(September 6, 2016), available at http://www.cmanet.org/news/detail/?article=cma-calls-for-greater-transparency-in
(on file with the California Initiative Review); see also Pension and Health Benefits Committee Agenda item 10,
CALPERS, https://www.calpers.ca.gov/docs/board-agendas/201606/pension/item-10.pdf (on file with the
California Initiative Review).
138
Why Patient Advocates and Health Providers Oppose 61, NO PROP 61 (August 22, 2016), available at
http://www.noprop61.com/facts/impact-on-health-care-providers (on file with the California Initiative
Review).
139
Joint Senate and Assembly Health Committee Informational Hearing, surpa note 1
140
CMA Calls for greater Transparency in prescription drug costs, CALIFORNIA MEDICAL ASSOCIATION (August 22,
2016), http://www.cmanet.org/news/detail/?article=cma-calls-for-greater-transparency-in (on file with the
California Initiative Review).

14

procedures.141 Because of these additional hurdles it is possible that treatment can be delayed or
a patient’s medications can be denied.142

3. Increase bureaucracy, red tape, lawsuits, and taxpayer costs.
The California Taxpayer Association is opposed to Proposition 61 and declared
implementation of this measure would be costly and lead to more government work.143
Additionally, the California Taxpayer Association claims that, clarifying the details of this
measure will likely require legal challenges because the measure is silent on whether the public
or confidential price paid by the VA would be controlling. The courts will also have to decide
how to resolve any issues resulting from Medi-Cal having to offer all FDA approved
medications, but manufacturers refusing to offer medications at a lower price.144
4. Increase state prescription drug costs.
Kathy Fairbanks, spokeswoman for the No on Proposition 61 campaign, argues that state
agencies get a better deal on medications than the VA.145 When asked to produce the
documentation, none can be provided. State agencies get rebates for certain prescription
medications that they use helping to offset the overall cost of prescription drug medications.146 If
this measure passes, those rebates could potentially be eliminated and the net price for
prescription medications will increase.147 The California Taxpayer Association also asserts that
this proposition will eliminate the supplemental rebates received by the Medi-Cal fee-for-service
program that total $233 million.148
D. Fiscal Considerations
There are too many factors to provide an estimate of any savings on the costs of
medications should Proposition 61 be enacted by the voters. When asked for a fiscal analysis of
the proposition, the LAO could not give an estimate because they cannot predict how
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pharmaceutical manufacturers will respond to this measure.149 Additionally, the state does not
know exactly how much true cost of medications are for the VA.150 State agencies may be
paying more for some medications and less for others because of the different populations the
state services compared to the population the VA covers.151

Scenario #1
If passed, one possible scenario is that the drug manufacturers will sell prescriptions to
the state at the lowest price equal to what the VA pays. This is what the measure seeks to
accomplish.152 The State would be buying the same drug for the same cost, but only for the
prescription drugs the VA purchases. However, it is impossible to estimate how much money the
state would save because the private VA prices are unknown.153

Scenario #2
Another scenario is that drug manufacturers will refuse to sell at the prices the VA pays.
This means the drug manufacturers would not be selling the lowest price paid for the same
prescription medications from the VA to the State.
In response to this, agencies may offer other medications that are not on the VA’s list
without any concerns about violating the measure because the price restrictions only apply to
medications that the VA offers.154 However, for the medications that the VA does offer, MediCal programs would be required to offer the medications at whatever price they are able to
negotiate because they are required by federal law to offer all medications approved by the
FDA.155 Due to the federal obligation, the Department of Health Care Services may have to
violate this measure in order to provide those medications.
Scenario #3
The last scenario the VA offered was that the drug manufacturers could just raise the
prices of prescription medications sold to the VA to shift their potential losses from the state.
Federal law provides that the VA gets an automatic 24 percent and up to an additional 40 off of
generic medications.156 The additional savings could be affected by this measure.
Ultimately, the LAO has not given any fiscal estimates because they feel any prediction
would be based in uncertainty.157
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If passed, Proposition 61 could have many unintended consequences. This proposition
would bind the state to paying the same price as the VA on medications that the VA covers.
However, the outcome of this measure is entirely dependent on how drug manufacturers respond.
If manufacturers agree to offer the state the same prices as the VA, then there are potential
savings that are impossible to predict because the confidential prices the VA pays for
prescription drugs are unknown. Manufacturers could also respond by raising the prices they
charge the VA to keep their profit levels consistent, as manufactures have done in the past when
Congress attempted to extend the savings the VA receives to Medicaid programs. Alternatively,
Manufacturers could respond by simply declining to offer the state the same prices the VA pays
for medications. The state would not be allowed to offer the medications the VA offers, but
could offer medications that are not on the VA’s list.
However, all the Medi-Cal programs that will be implicated by this measure will likely
have to disregard the measure because they are required by federal law to offer all medications
that are approved by the FDA. It is possible that there could be litigation to reach a decision on
this particular issue. Additionally, the possible changes in access to medications while the
particulars of the application are sorted out could have a negative impact on the lives of MediCal beneficiaries.
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